Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462969 | 0.98 | LMNA (0.39) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL29723099 | 0.98 | LMNA (0.39) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL29612249 | 0.95 | LMNA (0.38) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL1156717 | 0.95 | LMNA (0.38) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL27317473 | 0.84 | GABRA1 (0.42) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL2738303 | 0.81 | LMNA (0.38) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL13202844 | 0.81 | LMNA (0.38) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL7877780 | 0.80 | CYP3A4 (0.40) | LMNAGPR55CYP3A4HTT | |
| SCHEMBL12061470 | 0.79 | PDE2A (0.40) | LMNATRPA1SLC6A2HTR2BCHRM1 | |
| SCHEMBL12061474 | 0.79 | CYP3A4 (0.52) | LMNASLC6A2HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119505185-A | PAF supported ruthenium catalyst and preparation method and application thereof | 南昌大学 | 2025-02-25 | — | — | CN | claimed |
| CN-119409943-A | Ruthenium-containing catalyst and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-118724713-A | Synthesis method of fungus secondary metabolite ETHERICIN B | 贵州大学 | 2024-10-01 | — | — | CN | claimed |
| CN-117069692-B | 5-Hydroxypyrazole derivative, half-sandwich ruthenium complex, and preparation methods and applications thereof | 广西中医药大学 | 2024-08-27 | — | — | CN | claimed |
| CN-118184618-A | Gamma-caprolactone compound and preparation method and application thereof | 深圳市龙华区人民医院 | 2024-06-14 | — | — | CN | claimed |
| CN-117402186-A | Preparation method of nitrogen-silicon-oxygen fused heterocyclic compound | 五邑大学 | 2024-01-16 | — | — | CN | claimed |
| CN-115286609-B | Preparation method of 2-trifluoromethyl substituted dihydrobenzochromene | 浙江理工大学 | 2023-12-19 | — | — | CN | claimed |
| CN-117069692-A | 5-hydroxypyrazole derivative, half-sandwich ruthenium complex, and preparation methods and applications thereof | 广西中医药大学 | 2023-11-17 | — | — | CN | claimed |
| CN-113070101-B | Catalyst for decomposing formaldehyde and preparation method and application thereof | 苏州科技大学 | 2023-07-21 | — | — | CN | claimed |
| CN-116444406-A | Method for constructing tertiary carbon or quaternary carbon compound by oxygen-sulfur ylide through rearrangement reaction | 四川大学 | 2023-07-18 | — | — | CN | claimed |
| CN-111499538-B | Preparation method of (2S, 3R) -2-acylaminomethyl-3-hydroxybutyrate | 南方科技大学 | 2023-02-17 | — | — | CN | claimed |
| CN-115215895-A | Preparation method of five-membered silicon-containing fused heterocyclic compound | 五邑大学 | 2022-10-21 | — | — | CN | claimed |
| US-12258331-B2 | Pyrimidine derivative and preparation process and use thereof | GUANGDONG LEWWIN PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2025-03-25 | — | — | US | disclosed |
| CN-119661599-A | Preparation and application of N-heterocyclic carbene metal complex material | 福州大学 | 2025-03-21 | — | — | CN | disclosed |
| CN-119462781-A | Ligand, catalyst, chiral alcohol and synthesis method thereof | 深圳格林凯特医药技术有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119409943-A | Ruthenium-containing catalyst and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-115215895-A | Preparation method of five-membered silicon-containing fused heterocyclic compound | 五邑大学 | 2022-10-21 | — | — | CN | disclosed |
| CN-113651816-B | Chiral heterocyclic compound with hedgehog pathway antagonist activity and preparation method and application thereof | 苏州开拓药业股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-112920140-B | Preparation method of substituted urea compound | 中南大学 | 2022-07-22 | — | — | CN | disclosed |
| CN-112062767-B | Preparation method and intermediate of rumepilone | 杭州科巢生物科技有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258331-B2 | Pyrimidine derivative and preparation process and use thereof | MTR, HCCS, MET | LMNA 4624/4885TRPA1 3084/4885SLC6A2 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.